Introduction {#section5-2050312120918264}
============

Interstitial lung disease is a group of diffuse parenchymal lung disorders associated with substantial morbidity and mortality.^[@bibr1-2050312120918264]^ Drug-induced interstitial lung disease (DIILD) occurs when drug exposure causes inflammation and eventually fibrosis of the lung interstitium.^[@bibr2-2050312120918264]^ Chemotherapeutic drugs (e.g. bleomycin and gefitinib), amiodarone, anti-inflammatory drugs (e.g. methotrexate), biological drugs, and various other drugs can cause DIILD ([www.pneumotox.com](http://www.pneumotox.com)).^[@bibr2-2050312120918264],[@bibr3-2050312120918264]^ As DIILD is considered a serious adverse event (AE) and represents a serious clinical problem, all healthcare professionals should be aware of a potential DIILD as soon as possible. Early intervention may prevent the progression of AEs and permanent changes.^[@bibr4-2050312120918264]^ However, the detailed time-to-onset profiles of DIILD in clinical settings are not clear.

The frequency of DIILD is reported to be higher in Japan than that in other countries.^[@bibr5-2050312120918264]^ Lung injuries related to molecular-targeted drugs have been reported. Reports related to gefitinib first occurred in 2002 in Japan and those related to the antirheumatic drug leflunomide were reported 1 year later.^[@bibr5-2050312120918264]^ The Ministry of Health, Labor and Welfare in Japan has issued the Manual for Handling Disorders due to Adverse Drug Reactions with a focus on DIILD. AEs during the post-marketing phase in Japan are reported and managed by the Pharmaceuticals and Medical Devices Agency (PMDA). The agency has established a spontaneous reporting system (SRS) for the Japanese Adverse Drug Event Report (JADER) database. The JADER is the largest database in Japan and reflects the realities of clinical practices.

The aim of this retrospective pharmacovigilance study was to assess the incidence of DIILD by using the JADER database. We focused on the time-to-onset profile of DIILD. Furthermore, association rule mining has been proposed as a new analytical technique to identify undetected relationships such as possible risk factors between variables in the SRS database.^[@bibr6-2050312120918264],[@bibr7-2050312120918264]^ We evaluated potential association rules between DIILD and demographics.

Materials and methods {#section6-2050312120918264}
=====================

Data source {#section7-2050312120918264}
-----------

Healthcare professionals, marketing approval holders, patients, and consumers voluntarily send AE reports to the PMDA. All AE report data were accumulated in the PMDA and were fully anonymized by the PMDA to form the JADER database. JADER data from April 2004 to June 2018 are publicly available and can be downloaded from the PMDA website ([www.pmda.go.jp](http://www.pmda.go.jp)). For this retrospective study, we built a relational database, which integrated the data tables, by using the FileMaker Pro 13 software.

Definition of interstitial lung disease {#section8-2050312120918264}
---------------------------------------

In accordance with the terminology preferred by the Medical Dictionary for Regulatory Activities (MedDRA, [www.pmrj.jp/jmo/php/indexj.php](http://www.pmrj.jp/jmo/php/indexj.php)) version 19.0, we used the following preferred term (PT) for DIILD: *interstitial lung disease* (PT code: 10022611).

Drug selection {#section9-2050312120918264}
--------------

The number of drugs known to produce various patterns of DIILD is increasing. In this study, we first listed 82 drugs, each of which had more than 100 reported DIILD cases in the JADER database. Second, from the Drug-Induced Respiratory Disease Website ([www.pneumotox.com](http://www.pneumotox.com)), we listed 598 drugs from the website in the categories of interstitial/parenchymal lung disease, pulmonary edema---acute lung injury---ARDS, and pathology. From these categories, the following patterns were identified: "Interstitial/parenchymal lung disease: pneumonitis (ILD), acute, severe (may occasion an ARDS picture)" (pattern Ia, 155 listed drugs); "Interstitial/parenchymal lung disease: pneumonitis (ILD)" (pattern Ib, 329 listed drugs); "Interstitial/parenchymal lung disease: eosinophilic pneumonia (pulmonary infiltrates and eosinophilia)" (pattern Ic, 192 listed drugs); "Interstitial/parenchymal lung disease: pulmonary fibrosis (not otherwise specified)" (pattern Ig, 84 listed drugs); "Pulmonary edema---acute lung injury---ARDS" (pattern IIb, 254 listed drugs); "Pathology: cellular NSIP pattern" (pattern XVa, 51 listed drugs); "Pathology: organizing pneumonia (OP/BOOP) pattern" (pattern XVc, 70 listed drugs). Third, we compared the 598 listed drugs from the Drug-Induced Respiratory Disease Website ([www.pneumotox.com](http://www.pneumotox.com)) and the drugs in the JADER database with between 50 and 99 reported DIILD cases. Fourth, we listed the 18 drugs that matched the drugs in the Drug-Induced Respiratory Disease Website. Fifth, regardless of the number of reported DIILD cases related to each drug, we compared the drugs that were reported in the JADER database and drugs reported in previous studies.^[@bibr2-2050312120918264],[@bibr8-2050312120918264]^ Ten drugs (sirolimus, simvastatin, fluvastatin, daptomycin, lapatinib, interferon beta, interferon gamma, pravastatin, pitavastatin, and ipilimumab) that were not listed by the fourth procedure were added. In total, we identified 110 (82 + 18 + 10) drugs for analysis ([Table 1](#table1-2050312120918264){ref-type="table"}). Thus, [Table 1](#table1-2050312120918264){ref-type="table"} is considered to include almost all drugs that can be practically analyzed.

###### 

Number of reports and ROR for drug-induced interstitial lung disease.

![](10.1177_2050312120918264-table1)

  Category                                                           ATC code^[a](#table-fn2-2050312120918264){ref-type="table-fn"}^   Drugs                                        Total (n)   Case (n)   Non-case (n)   ROR^[b](#table-fn3-2050312120918264){ref-type="table-fn"}^ (95% CI)
  ------------------------------------------------------------------ ----------------------------------------------------------------- -------------------------------------------- ----------- ---------- -------------- ---------------------------------------------------------------------
                                                                                                                                       Total                                        534688      24123      --             --
  H2-receptor antagonists                                            A02BA03                                                           Famotidine                                   3469        172        3297           1.1 (0.9--1.3)
  Proton pump inhibitors                                             A02BC03                                                           Lansoprazole                                 4434        240        4194           1.2 (1.1--1.4)
  Aminosalicylic acid and similar agents                             A07EC01                                                           Salazosulfapyridine                          1864        108        1756           1.3 (1.1--1.6)
                                                                     A07EC02                                                           Mesalazine                                   1558        133        1425           2.0 (1.7--2.4)
  Dipeptidyl peptidase 4 (DPP-4) inhibitors                          A10BH01                                                           Sitagliptin                                  2054        148        1906           1.6 (1.4--1.9)
                                                                     A10BH02                                                           Vildagliptin                                 2371        74         2297           0.7 (0.5−0.9)
  Platelet aggregation inhibitors                                    B01AC04                                                           Clopidogrel                                  4638        229        4409           1.1 (0.9--1.3)
                                                                     B01AC05                                                           Ticlopidine                                  2180        57         2123           0.6 (0.4−0.7)
                                                                     B01AC23                                                           Cilostazol                                   2244        107        2137           1.1 (0.9−1.3)
  Direct thrombin inhibitors                                         B01AE07                                                           Dabigatran                                   2466        92         2374           0.8 (0.7−1.0)
  Direct factor Xa inhibitors                                        B01AF01                                                           Rivaroxaban                                  4691        165        4526           0.8 (0.7--0.9)
                                                                     B01AF02                                                           Apixaban                                     4800        133        4667           0.6 (0.5--0.7)
  Antiarrhythmics, class III                                         C01BD01                                                           Amiodarone                                   1993        665        1328           10.9 (9.9--11.9)
  Dihydropyridine derivatives                                        C08CA01                                                           Amlodipine                                   3672        100        3572           0.6 (0.5−0.7)
  Phenylalkylamine derivatives                                       C08EA02                                                           Bepridil                                     734         133        601            4.7 (3.9--5.7)
  Angiotensin II receptor blockers (ARBs), plain                     C09CA03                                                           Valsartan                                    3548        131        3417           0.8 (0.7--1.0)
                                                                     C09CA06                                                           Candesartan                                  1925        121        1804           1.4 (1.2--1.7)
  HMG CoA reductase inhibitors                                       C10AA01                                                           Simvastatin                                  318         14         304            1.0 (0.6--1.7)
                                                                     C10AA03                                                           Pravastatin                                  922         40         882            1.0 (0.7--1.3)
                                                                     C10AA04                                                           Fluvastatin                                  638         19         619            0.6 (0.4--1.0)
                                                                     C10AA05                                                           Atorvastatin                                 2748        104        2644           0.8 (0.7--1.0)
                                                                     C10AA07                                                           Rosuvastatin                                 1517        71         1446           1.0 (0.8--1.3)
                                                                     C10AA08                                                           Pitavastatin                                 813         41         772            1.1 (0.8--1.5)
  Glucocorticoids                                                    H02AB02                                                           Dexamethasone                                5952        144        5808           0.5 (0.4--0.6)
  Tetracyclines                                                      J01AA08                                                           Minocycline                                  1637        152        1485           2.2 (1.8--2.6)
  Carbapenems                                                        J01DH02                                                           Meropenem                                    1940        103        1837           1.2 (0.97−1.4)
  Combinations of sulfonamides and trimethoprim, incl. derivatives   J01EE01                                                           Sulfamethoxazole • Trimethoprim              2737        104        2633           0.8 (0.7−1.0)
  Macrolides                                                         J01FA09                                                           Clarithromycin                               4066        101        3965           0.5 (0.4−0.7)
  Fluoroquinolones                                                   J01MA12                                                           Levofloxacin                                 4187        196        3991           1.0 (0.9--1.2)
  Other antibacterials                                               J01XX09                                                           Daptomycin                                   353         20         333            1.3 (0.8--2.0)
  Antibiotics                                                        J04AB02                                                           Rifampicin                                   1600        76         1524           1.1 (0.8−1.3)
  Other drugs for treatment of tuberculosis                          J04AK02                                                           Ethambutol                                   1253        50         1203           0.9 (0.7−1.2)
  Antivirals for treatment of HCV infections                         J05AP01                                                           Ribavirin                                    10394       319        10075          0.7 (0.6--0.7)
  Nitrogen mustard analogues                                         L01AA01                                                           Cyclophosphamide                             5129        390        4739           1.8 (1.6--1.9)
  Folic acid analogues                                               L01BA01                                                           Methotrexate                                 18336       1899       16437          2.6 (2.4--2.7)
                                                                     L01BA04                                                           Pemetrexed                                   2431        347        2084           3.6 (3.2--4.0)
  Pyrimidine analogues                                               L01BC02                                                           Fluorouracil                                 7796        801        6995           2.5 (2.3--2.7)
                                                                     L01BC05                                                           Gemcitabine                                  4454        1161       3293           7.8 (7.3--8.3)
                                                                     L01BC06                                                           Capecitabine                                 3561        209        3352           1.3 (1.1-1.5)
                                                                     L01BC53                                                           Tegafur U+002E; Uracil                       1635        108        1527           1.5 (1.2--1.8)
                                                                     L01BC53                                                           Tegafur U+002E; Gimeracil U+002E; Oteracil   6618        639        5979           2.3 (2.1--2.5)
  Vinca alkaloids and analogues                                      L01CA02                                                           Vincristine                                  2939        145        2794           1.1 (0.9--1.3)
                                                                     L01CA04                                                           Vinorelbine                                  758         175        583            6.4 (5.4--7.6)
  Podophyllotoxin derivatives                                        L01CB01                                                           Etoposide                                    3017        123        2894           0.9 (0.7--1.1)
  Taxanes                                                            L01CD01                                                           Paclitaxel                                   6900        944        5956           3.5 (3.2--3.7)
                                                                     L01CD02                                                           Docetaxel                                    6403        1066       5337           4.4 (4.1--4.7)
  Anthracyclines and related substances                              L01DB01                                                           Doxorubicin                                  3804        186        3618           1.1 (0.9--1.3)
                                                                     L01DB03                                                           Epirubicin                                   1547        138        1409           2.1 (1.7--2.5)
                                                                     L01DB10                                                           Amrubicin                                    1245        116        1129           2.2 (1.8--2.6)
  Other cytotoxic antibiotics                                        L01DC01                                                           Bleomycin                                    418         104        314            7.0 (5.6--8.8)
  Platinum compounds                                                 L01XA01                                                           Cisplatin                                    8673        260        8413           0.7 (0.6--0.7)
                                                                     L01XA02                                                           Carboplatin                                  5281        332        4949           1.4 (1.3--1.6)
                                                                     L01XA03                                                           Oxaliplatin                                  8001        682        7319           2.0 (1.8--2.2)
  Monoclonal antibodies                                              L01XC02                                                           Rituximab                                    3979        209        3770           1.2 (1.0--1.4)
                                                                     L01XC03                                                           Trastuzumab                                  2469        380        2089           3.9 (3.5--4.3)
                                                                     L01XC06                                                           Cetuximab                                    2746        451        2295           4.2 (3.8--4.7)
                                                                     L01XC07                                                           Bevacizumab                                  9440        505        8935           1.2 (1.1--1.3)
                                                                     L01XC08                                                           Panitumumab                                  1393        302        1091           5.9 (5.2--6.7)
                                                                     L01XC11                                                           Ipilimumab                                   545         41         504            1.7 (1.3--2.4)
                                                                     L01XC13                                                           Pertuzumab                                   683         122        561            4.6 (3.8--5.6)
                                                                     L01XC17                                                           Nivolumab                                    4419        991        3428           6.3 (5.9--6.8)
                                                                     L01XC18                                                           Pembrolizumab                                2148        622        1526           8.8 (8.0--9.7)
                                                                     L01XC21                                                           Ramucirumab                                  1570        91         1479           1.3 (1.1−1.6)
  Protein kinase inhibitors                                          L01XE01                                                           Imatinib                                     4399        348        4051           1.8 (1.6--2.0)
                                                                     L01XE02                                                           Gefitinib                                    2736        1217       1519           17.8 (16.5--19.2)
                                                                     L01XE03                                                           Erlotinib                                    2748        836        1912           9.6 (8.8--10.4)
                                                                     L01XE04                                                           Sunitinib                                    3320        106        3214           0.7 (0.6--0.8)
                                                                     L01XE05                                                           Sorafenib                                    4922        136        4786           0.6 (0.5--0.7)
                                                                     L01XE06                                                           Dasatinib                                    1256        85         1171           1.5 (1.2--1.9)
                                                                     L01XE07                                                           Lapatinib                                    731         36         695            1.1 (0.8--1.5)
                                                                     L01XE09                                                           Temsirolimus                                 652         300        352            18.3 (15.6--21.3)
                                                                     L01XE10                                                           Everolimus                                   3671        1093       2578           9.4 (8.7--10.0)
                                                                     L01XE13                                                           Afatinib                                     786         178        608            6.2 (5.3--7.4)
                                                                     L01XE16                                                           Crizotinib                                   1027        147        880            3.6 (3.0--4.2)
                                                                     L01XE35                                                           Osimertinib                                  653         241        412            12.5 (10.7-14.7)
                                                                     L01XE36                                                           Alectinib                                    243         81         162            10.6 (8.1--13.9)
  Other antineoplastic agents                                        L01XX19                                                           Irinotecan                                   5545        650        4895           2.9 (2.6--3.1)
                                                                     L01XX32                                                           Bortezomib                                   2219        153        2066           1.6 (1.3--1.9)
                                                                     L01XX33                                                           Celecoxib                                    3222        110        3112           0.7 (0.6--0.9)
                                                                     L01XX41                                                           Eribulin                                     840         104        736            3.0 (2.4−3.7)
  Gonadotropin releasing hormone analogues                           L02AE02                                                           Leuprorelin                                  1436        229        1207           4.0 (3.5--4.7)
  Anti-androgens                                                     L02BB03                                                           Bicalutamide                                 849         255        594            9.2 (7.9--10.6)
  Colony stimulating factors                                         L03AA02                                                           Filgrastim                                   635         117        518            4.8 (3.9−5.9)
  Interferons                                                        L03AB02                                                           Interferon beta                              1555        38         1517           0.5 (0.4--0.7)
                                                                     L03AB03                                                           Interferon gamma                             32          6          26             4.9 (2.0--11.9)
                                                                     L03AB11                                                           PEG INF-2α                                   3386        305        3081           2.1 (1.9--2.4)
  Selective immunosuppressants                                       L04AA10                                                           Sirolimus                                    44          5          39             2.7 (1.1--6.9)
                                                                     L04AA13                                                           Leflunomide                                  630         55         575            2.0 (1.5--2.7)
                                                                     L04AA24                                                           Abatacept                                    1186        84         1102           1.6 (1.3−2.0)
                                                                     L04AA29                                                           Tofacitinib                                  981         74         907            1.7 (1.4--2.2)
  Tumor necrosis factor alpha (TNF-α) inhibitors                     L04AB01                                                           Etanercept                                   4050        402        3648           2.4 (2.1--2.6)
                                                                     L04AB02                                                           Infliximab                                   4605        347        4258           1.7 (1.6--1.9)
                                                                     L04AB04                                                           Adalimumab                                   2452        227        2225           2.2 (1.9--2.5)
                                                                     L04AB05                                                           Certolizumab Pegol                           863         66         797            1.8 (1.4−2.3)
                                                                     L04AB06                                                           Golimumab                                    1047        86         961            1.9 (1.5−2.4)
  Interleukin inhibitors                                             L04AC07                                                           Tocilizumab                                  4187        209        3978           1.1 (0.97--1.3)
  Calcineurin inhibitors                                             L04AD01                                                           Ciclosporin                                  6602        121        6481           0.4 (0.3--0.5)
                                                                     L04AD02                                                           Tacrolimus                                   10478       268        10210          0.6 (0.5--0.6)
  Other immunosuppressants                                           L04AX04                                                           Lenalidomide                                 4247        99         4148           0.5 (0.4−0.6)
  Acetic acid derivatives and related substances                     M01AB05                                                           Diclofenac                                   3552        106        3446           0.6 (0.5−0.7)
  Propionic acid derivatives                                         M01AE                                                             Loxoprofen                                   6372        304        6068           1.1 (0.9--1.2)
  Penicillamine and similar agents                                   M01CC02                                                           Bucillamine                                  1095        251        844            6.4 (5.5--7.3)
  Preparations inhibiting uric acid production                       M04AA01                                                           Allopurinol                                  3202        142        3060           1.0 (0.8--1.2)
  Salicylic acid and derivatives                                     N02BA01                                                           Aspirin (acetylsalicylic acid)               7477        109        7368           0.3 (0.3−0.4)
  Carboxamide derivatives                                            N03AF01                                                           Carbamazepine                                5568        76         5492           0.3 (0.2−0.4)
  Other antiepileptics                                               N03AX16                                                           Pregabalin                                   4659        158        4501           0.7 (0.6--0.9)
  Detoxifying agents for antineoplastic treatment                    V03AF04                                                           Levofolinate                                 3989        410        3579           2.4 (2.2--2.7)
  Herbal Medicines                                                                                                                     Sai-rei-to                                   325         132        193            14.5 (11.7--18.2)
                                                                                                                                       Sho-saiko-to                                 152         66         86             16.3 (11.8--22.4)
  Others                                                                                                                               Iguratimod                                   487         86         401            4.6 (3.6−5.7)

ROR: reporting odds ratio; CI: confidence interval; HCV: Hepatitis C Virus.

Anatomical therapeutic classification.

Reporting odds ratio.

Statistics {#section10-2050312120918264}
----------

### Reporting odds ratio {#section11-2050312120918264}

The reporting odds ratio (ROR) is the authorized pharmacovigilance index and was calculated using two-by-two contingency tables of the presence or absence of a particular drug and a particular AE in the case reports.^[@bibr9-2050312120918264]^ An association was considered disproportionate when the lower limit of the 95% confidence interval (CI) was \>1 ([Figure 1](#fig1-2050312120918264){ref-type="fig"}).^[@bibr9-2050312120918264],[@bibr10-2050312120918264]^ Two or more cases were required to define the signal.^[@bibr11-2050312120918264]^

![Two-by-two contingency table for analysis.](10.1177_2050312120918264-fig1){#fig1-2050312120918264}

### Time to onset {#section12-2050312120918264}

Time-to-onset duration was calculated from the time of the patient's first prescription to the occurrence of the AEs.^[@bibr7-2050312120918264],[@bibr12-2050312120918264]^ It is necessary to take the correct truncation into account when estimating the time to onset of AEs from SRS data. We chose an analysis period of 730 days after the start date of administration to focus attention on the onset of AEs within 2 years. The median duration, quartiles, and the Weibull shape parameters (WSPs) were used to evaluate the time-to-onset data.^[@bibr7-2050312120918264],[@bibr12-2050312120918264]^ The scale parameter, α, of the Weibull distribution determines the scale of the distribution function. A larger scale value stretches the distribution, whereas a smaller scale value shrinks the data distribution. The shape parameter, β, of the Weibull distribution determines the shape of the distribution function. A larger shape value produces a left-skewed curve, whereas a smaller shape value produces a right-skewed curve. In the analysis of the SRS, the shape parameter of the Weibull distribution was used to indicate hazards without a reference population as follows: when β was equal to 1, the hazard was estimated to be constant over time; if β was greater than 1 and the 95% confidence interval (CI) of β excluded the value 1, the hazard was considered to increase over time (wear-out failure type); finally, if β was less than 1 and the 95% CI of β excluded the value 1, the hazard was considered to decrease over time (initial-failure type).^[@bibr7-2050312120918264],[@bibr13-2050312120918264][@bibr14-2050312120918264][@bibr15-2050312120918264][@bibr16-2050312120918264]--[@bibr17-2050312120918264]^ Data analyses were performed by using JMP, version 12.0.1 (SAS Institute Inc., Cary, NC, USA).

### Association rule mining {#section13-2050312120918264}

Association rule mining has been proposed as an analytical approach for discovering interesting relationships among the possible risk factors and variables in the SRS database. The method is focused on finding frequent co-existing associations among a collection of items.^[@bibr6-2050312120918264],[@bibr7-2050312120918264]^ Given a set of transactions T (each transaction is a set of items), an association rule can be expressed as X (the antecedent (left-hand-side, lhs) of the rule) → Y (the consequent (right-hand-side, rhs) of the rule), where X and Y are mutually exclusive sets of items.^[@bibr6-2050312120918264],[@bibr7-2050312120918264]^ The *Apriori* algorithm was applied to find association rules. *Support, confidence*, and *lift* were used as indicators to decide the relative strength of the rules. These indices were calculated as follows:

$$\begin{array}{l}
\begin{array}{l}
{Support = {Number}\ {of}\ {transactions}\ {with}\ {both}\ } \\
{X\ {and}\ {Y/Total}\ {number}\ {of}\ {transactions}\  =} \\
\end{array} \\
{\left\{ X\  \cap \ Y \right\}/\left\{ D \right\} = P\ (X\  \cap \ Y)} \\
\end{array}$$

$$\begin{array}{l}
\begin{array}{l}
{Confidence = {Number}\ {of}\ {transactions}\ {with}\ {both}\ } \\
{X\ {and}\ {Y/Total}\ {number}\ {of}\ {transactions}\ {with}\ X = \ } \\
\end{array} \\
{P\ (X\  \cap \ Y)/P\ (X)} \\
\end{array}$$

*Confidence* corresponds to the conditional probability P (Y\|X) and *Confidence* measures the reliability of the interf Confidence erence made by a rule.

$$\begin{array}{l}
{Expected\ confidence = {Number}\ {of}\ {transactions}\ {with}\ Y/} \\
{\mspace{40mu}\mspace{40mu}{Total}\ {number}\ {of}\ {transactions}\  = P\left( B \right)} \\
\end{array}$$

$$\begin{array}{l}
{Lift = Confidence/Expected\ Confidence} \\
{= P\ (X\  \cap \ Y)/P\ (X)\ P\ (Y)} \\
\end{array}$$

*Lift* is the factor by which the co-occurrence of X and Y exceeds the expected probability of X and Y co-occurring, had they been independent. *Lift* is the ratio between the *confidence* of the rule and the *support* of the itemset as a consequence of the rule. The *lift* can be expressed as the confidence divided by P (Y). The *lift* can be evaluated as follows: *lift* = 1, if X and Y are independent; *lift* \> 1, if X and Y are positively correlated; *lift* \< 1, if X and Y are negatively correlated. Furthermore, we calculated the chi-square values to evaluate the association rules^[@bibr18-2050312120918264]^

$$\begin{array}{l}
{Chi-squared =} \\
{D{(lift - 1)}^{2}\frac{Support*Confidence}{(Confidence - Support)*(Lift - Confidence)}} \\
\end{array}$$

Association rule mining was performed using the *apriori* function of the *arules* library in the *arules* package of the R software (version 3.3.3). *Support* and *lift* were visualized using the R-extension package *arulesViz* which implements novel visualization techniques to explore association rules.

Results {#section14-2050312120918264}
=======

The JADER database contained 534,688 reports. The number of AE reports corresponding to DIILD was 24,123 reports ([Table 1](#table1-2050312120918264){ref-type="table"}). The number of AEs associated with the top 10 reported drugs, methotrexate, gefitinib, gemcitabine, everolimus, docetaxel, nivolumab, paclitaxel, erlotinib, fluorouracil, and oxaliplatin was 1899, 1217, 1161, 1093, 1066, 991, 944, 836, 801, and 682, respectively. The top 10 RORs (95% CIs) with drugs, temsirolimus, gefitinib, sho-saiko-to, sai-rei-to, osimertinib, amiodarone, alectinib, erlotinib, everolimus, and bicalutamide were 18.3 (15.6--21.3), 17.8 (16.5--19.2), 16.3 (11.8--22.4), 14.5 (11.7--18.2), 12.5 (10.7--14.7), 10.9 (9.9--11.9), 10.6 (8.1--13.9), 9.6 (8.8--10.4), 9.4 (8.7--10.0), and 9.2 (7.9--10.6), respectively. In contrast, the ROR signals of HMG CoA reductase and antithrombotic agents such as platelet aggregation inhibitors, direct thrombin inhibitors, and direct factor Xa inhibitors were not detected.

For the time-to-onset analysis, we extracted combinations that had complete information for the date of treatment initiation and the date of AE onset. The median durations (day) (interquartile range) for DIILD were as follows: amiodarone (123.0 (27.0--400.5)), methotrexate (145.5 (67.8--475.8)), fluorouracil (86.0 (35.5--181.3)), gemcitabine (53.0 (20.0--83.0)), paclitaxel (52.0 (28.5--77.5)), docetaxel (47.0 (18.8--78.3)), bleomycin (92.0 (38.0--130.5)), oxaliplatin (45.0 (11.0--180.0)), nivolumab (56.0 (21.0--135.0)), gefitinib (24.0 (11.0--55.0)), erlotinib (21.0 (9.0--49.0)), temsirolimus (38.0 (14.0--68.5)), everolimus (56.0 (35.0--90.0)), osimertinib (51.5 (21.0--84.8)), alectinib (78.5 (44.3--145.8)), bicalutamide (50.0 (28.0--147.0)), PEG IFN-2α (140.0 (75.8--233.0)), sai-rei-to (35.0 (20.0--54.5)), and sho-saiko-to (33.0 (13.5--74.0)) days, respectively ([Figure 2](#fig2-2050312120918264){ref-type="fig"}). Among the drugs which demonstrated the lower limit of the 95% CI of the ROR was \>1, \>50% of the DIILD cases associated with minocycline, amrubicin, carboplatin, gefitinib, erlotinib, dasatinib, afatinib, crizotinib, bortezomib, filgrastim, or certolizumab pegol were observed within 4 weeks. \>50% of the reports of DIILD following administration of amiodarone, methotrexate, PEG IFN-2α, leflunomide, or etanercept were recorded more than 4 months of treatment initiation. The WSP β (95% CI) of amiodarone, nivolumab, gefitinib, and sho-saiko-to was 0.77 (0.70--0.84), 0.90 (0.85--0.95), 0.78 (0.74--0.82), and 0.76 (0.59--0.95), respectively. The lower limits of the 95% CI of the WSP β value for daptomycin, vinorelbine, paclitaxel, amrubicin, bevacizumab, everolimus, and PEG INF-2α were greater than 1.

![A box plot of drug-induced interstitial lung disease. The bottom end is minimum value. The top end is maximum value. The bottom of black box is 25th percentile. The top of white box is 75th percentile. The line joining the white and black is median. Panel A contains the drugs from ATC code A02BA03 to ATC code L01XA03 in the [Table 1](#table1-2050312120918264){ref-type="table"}. Panel B contains the drugs from ATC code L01XC02 to ATC code V03AF04 in the [Table 1](#table1-2050312120918264){ref-type="table"}.](10.1177_2050312120918264-fig2){#fig2-2050312120918264}

To evaluate the risk factors for DIILD by using demographic data, such as age, patient history, and administered drugs, we applied the *Apriori* algorithm (minimum *support* and minimum *confidence* threshold, 0.00001 and 0.01, respectively) and *maxlen* was restricted to 3. The result of the mining algorithm for DIILD was a set of 11 rules, respectively ([Table 2](#table2-2050312120918264){ref-type="table"}). {sho-saiko-to, 50--59 years}, {sho-saiko-to, 60--69 years}, {sho-saiko-to, 70--79 years}  ⇒ {DIILD}, {sho-saiko-to-ka-kikyo-sekko, 70--79 years}  ⇒ {DIILD} demonstrated high *lift* scores ([Table 2](#table2-2050312120918264){ref-type="table"}, id(8--11) and [Figure 3](#fig3-2050312120918264){ref-type="fig"}). The association rules of the combination of {amiodarone, 50--59 years}, {amiodarone, 60--69 years}, {amiodarone, 70--79 years}, {amiodarone, 80--89 years}, {amiodarone, ⩾ 90 years}  ⇒ {DIILD} demonstrated high *support* and *lift* scores ([Table 2](#table2-2050312120918264){ref-type="table"}, id(3--7) and [Figure 3](#fig3-2050312120918264){ref-type="fig"}).

###### 

Association parameters of rules of Drug-Induced Interstitial Lung Disease (DIILD) based on the administered drug and the stratified age group (sort by lift).

![](10.1177_2050312120918264-table2)

  Id       lhs^[a](#table-fn4-2050312120918264){ref-type="table-fn"}^       rhs^[b](#table-fn5-2050312120918264){ref-type="table-fn"}^   *Support*   *Confidence*   *Lift*   χ^2^
  -------- ------------------------------------------------------------ --- ------------------------------------------------------------ ----------- -------------- -------- ----------------------------------------------------------------
  \[1\]    {amiodarone, 40--49 years}                                   ⇒   {DIILD}                                                      0.00015     0.52288        1.17     3.52
  \[2\]    {amiodarone, 30--39 years}                                   ⇒   {DIILD}                                                      0.00001     0.06667        1.49     0.90
  \[3\]    {amiodarone, 50--59 years}                                   ⇒   {DIILD}                                                      0.00011     0.18182        4.06     142.24^[c](#table-fn6-2050312120918264){ref-type="table-fn"}^
  \[4\]    {amiodarone, ⩾ 90 years}                                     ⇒   {DIILD}                                                      0.00019     0.21277        4.75     315.56^[c](#table-fn6-2050312120918264){ref-type="table-fn"}^
  \[5\]    {amiodarone, 60--69 years}                                   ⇒   {DIILD}                                                      0.00034     0.27492        6.14     820.47^[c](#table-fn6-2050312120918264){ref-type="table-fn"}^
  \[6\]    {amiodarone, 70--79 years}                                   ⇒   {DIILD}                                                      0.00048     0.29702        6.64     1288.35^[c](#table-fn6-2050312120918264){ref-type="table-fn"}^
  \[7\]    {amiodarone, 80--89 years}                                   ⇒   {DIILD}                                                      0.00025     0.29797        6.66     673.40^[c](#table-fn6-2050312120918264){ref-type="table-fn"}^
  \[8\]    {sho-saiko-to, 50--59 years}                                 ⇒   {DIILD}                                                      0.00019     0.03030        6.77     505.12^[c](#table-fn6-2050312120918264){ref-type="table-fn"}^
  \[9\]    {sho-saiko-to-ka-kikyo-sekko, 70--79 years}                  ⇒   {DIILD}                                                      0.00011     0.31579        7.06     320.15^[c](#table-fn6-2050312120918264){ref-type="table-fn"}^
  \[10\]   {sho-saiko-to, 70--79 years}                                 ⇒   {DIILD}                                                      0.00049     0.38806        8.67     1863.67^[c](#table-fn6-2050312120918264){ref-type="table-fn"}^
  \[11\]   {sho-saiko-to, 60--69 years}                                 ⇒   {DIILD}                                                      0.00036     0.48718        10.89    1810.41^[c](#table-fn6-2050312120918264){ref-type="table-fn"}^

lhs: left-hand-side (antecedents).

rhs: right-hand-side (consequents).

Statistical significance: χ^2^ value ⩾ 4.

![Association rules for drug-induced interstitial lung disease based on the JADER database between April 2004 and June 2018. The arguments of plot in the *arulesViz* were set as follows: method = "graph," measure = "*support*," shading = "*lift*." The measures of *support* were used in visualization as area of circle. The measures of *lift* were used for the shading of color of the circle. *Support* and *lift* were visualized using the R-extension package *arulesViz* which implements novel visualization techniques to explore association rules.](10.1177_2050312120918264-fig3){#fig3-2050312120918264}

Discussion {#section15-2050312120918264}
==========

In this study, we evaluated the relationship between the drug and DIILD by using data from the SRS database. The exact frequency of drug-induced pulmonary toxicity is unknown.^[@bibr3-2050312120918264]^ Although global incidence of DIILD is not clearly known, at least 2.5%--3.0% of cases are drug induced.^[@bibr19-2050312120918264],[@bibr20-2050312120918264]^ Several studies have indicated that drug-induced pulmonary toxicity is underdiagnosed worldwide.^[@bibr3-2050312120918264]^ We summarized the incidence of DIILD, the ROR values, and time-to-onset profile from the SRS database. It is considered to be more comprehensive information indicating the occurrence of DIILD reflecting the actual clinical use than has been published previously.

DIILD can occur at any time during treatment.^[@bibr21-2050312120918264]^ We applied time-to-onset analysis to validate the results, and found that \>50% of the DIILD cases associated with carboplatin, gefitinib, erlotinib, dasatinib, afatinib, crizotinib, bortezomib, and so on were observed within 4 weeks in the real-world data set. DIILD occurring after 4 months of amiodarone, methotrexate, PEG IFN-2α, leflunomide, or etanercept administration should not be overlooked.

It is suggested that risk factors for amiodarone-related DIILD were cumulative dose, and a combination of high doses over longer periods.^[@bibr22-2050312120918264]^ The cumulative incidence of amiodarone-related DIILD was 4.2%, 7.8%, and 10.6% after 1, 3, and 5 years, respectively, during 48-month follow-up periods in a retrospective study.^[@bibr23-2050312120918264]^ The time-to-onset duration of amiodarone was 123.0 days in our study using the JADER data set. Amiodarone-related DIILD was likely to be initial-failure type. For methotrexate, Kremer et al.^[@bibr24-2050312120918264]^ reported a mean time to DIILD onset of 23 days (range = 3--112 days). In other studies, time to DIILD onset has been as long as 4 years.^[@bibr25-2050312120918264]^ The onset of DIILD due to methotrexate was 145.5 days in our study. A nationwide Japanese study of gemcitabine determined a median time of onset of 65 days.^[@bibr2-2050312120918264]^ The onset of DIILD due to gemcitabine was 53.0 days in our study. The median DIILD initiation time in patients with germ cell tumors receiving high-dose bleomycin was 4.2 months (126 days).^[@bibr26-2050312120918264]^ The median DIILD initiation time of bleomycin was 92.0 days in our study. DIILD onset of epidermal growth factor receptor (EGFR)-directed monoclonal antibodies such as cetuximab and panitumumab demonstrated a broad range of times (median = 101 days, range = 17--431 days).^[@bibr27-2050312120918264]^ The time-to-onset durations of cetuximab and panitumumab were 45.0 and 55.0 days in our study, respectively. For immune checkpoint inhibitors such as programmed cell death 1 (PD-1) inhibitors (nivolumab (DIILD onset in the JADER data set: 56.0 days), pembrolizumab (DIILD onset in the JADER data set: 40.0 days)), time to onset ranged from 0.2 to 27.4 months, with DIILD occurring within 2 months of treatment initiation in 42% of patients.^[@bibr2-2050312120918264]^ No clear relationship has been observed between DIILD onset and dose or duration of treatment.^[@bibr28-2050312120918264]^ Gefitinib (DIILD onset in the JADER data set: 24.0 days) and erlotinib (DIILD onset in the JADER data set: 21.0 days) are EGFR-targeting agents. The incidence of DIILD associated with gefitinib and erlotinib was highest within 4 weeks (28 days) of the initiation of treatment.^[@bibr29-2050312120918264],[@bibr30-2050312120918264]^ DIILD induced by gefitinib was likely to be initial-failure type. Crizotinib, an oral tyrosine kinase inhibitor, induced DIILD several months after the initiation of treatment (median, 8.5 (6.5--11.5) months (255 days)).^[@bibr31-2050312120918264]^ In contrast, the onset of DIILD due to crizotinib was 17.0 days in our study. A distinct discrepancy in crizotinib was observed in the time-to-onset duration between the literature data and our result; however, we do not have a plausible explanation for this discrepancy. For leflunomide (DIILD onset in the JADER data set: 131.5 days), DIILD was reported in most patients within 20 weeks (140 days) in a study in Japan.^[@bibr32-2050312120918264]^ Our findings for the time to onset were not clearly linked to the literature data. However, we could demonstrate similar trends in most of the drugs considered in this study. Information from the SRS database and the literature data might be considered complementary.

There are many unclear points about the causative substances and underlying mechanisms of DIILD, which is diagnosed on the basis of clinical, physiological, and radiological findings consistent with interstitial lung disease.^[@bibr2-2050312120918264]^ Some of the known risk factors of DIILD include follows: age, drug interaction, genetic variations, ethnicity, dose, sex, radiation-induced lung injury, pulmonary edema, smoking, progression of the underlying disease, and use or non-use of corticosteroid therapy.^[@bibr3-2050312120918264],[@bibr4-2050312120918264]^

In general, old age is associated with an increased risk of drug toxicity.^[@bibr3-2050312120918264]^ In a retrospective review of the pulmonary toxicity of bleomycin, Simpson et al.^[@bibr33-2050312120918264]^ showed that for cases in which pulmonary toxicity was fatal, the patients were older than the remaining patients, and in patients aged over 40 years, especially those with renal function in the lower range of normal, the risk of developing fatal toxicity might exceed 10%.^[@bibr3-2050312120918264]^ We detected the possible association rule related to DIILD for the combination of sho-saiko-to or amiodarone and aging (⩾50 years). Furthermore, the other rule of association {sho-saiko-to-ka-kikyo-sekko, 70--79 years} was observed in the antecedent (lhs). Thus, elderly patients receiving sho-saiko-to or amiodarone should be advised to adhere to appropriate treatment plan.

Sho-saiko-to contains seven crude drugs.^[@bibr34-2050312120918264]^ Among them, *Bupleurum* root and *Scutellaria* root are thought to be the potential causes of lung injury.^[@bibr34-2050312120918264]^ Many Chinese herbal medicines contain *Bupleurum* root and *Scutellaria* root, and herbal medicines such as saiko-ka-ryukotsu-borei-to and sai-rei-to can induce DIILD in a manner similar to that associated with sho-saiko-to.^[@bibr35-2050312120918264],[@bibr36-2050312120918264]^ It remains to be elucidated whether one or both drugs affect the lungs. Until then, it is a reasonable assumption that DIILD associated with sho-saiko-to was caused by *Bupleurum* root and *Scutellaria* root.^[@bibr34-2050312120918264]^

Drug interaction by concomitant drug use is a risk factor of AEs. As people age, they develop more chronic diseases and, accordingly, use more drugs. It is reported that amiodarone inhibits CYP1A2, CYP3A4, CYP2C9, and CYP2D6.^[@bibr37-2050312120918264][@bibr38-2050312120918264]--[@bibr39-2050312120918264]^ As the medication that is metabolized by any of these enzymes will be affected by plasma levels, it is likely that patients using amiodarone use other drugs which might increase the risk to DIILD occurrence. We evaluated the dose dependency of amiodarone on DIILD. The average dose of amiodarone for cases with DIILD (n = 778) and without DIILD (n = 1351) was 211.2 ± 154.3 (mean ± standard deviation) and 191.4 ± 174.9 mg/day, respectively. There were no statistically significant differences in our results. We did not evaluate the effects of concomitant drugs further.

Gefitinib plasma levels might be affected when using drugs that are metabolized by CYP2D6, such as metoprolol.^[@bibr37-2050312120918264],[@bibr38-2050312120918264]^ In our study, the number of all AE reports related to gefitinib was 2736. The number of cases of DIILD related to gefitinib was 1217. The combination of gefitinib and metoprolol was 8, and 4 cases were related to DIILD among them (8 cases). We did not examine the potential drug-by-drug bias of gefitinib and metoprolol because there were too few cases for a robust analysis.

Erlotinib and smoking are also a bad combination because of the induction of CYP1A2 and the subsequent lower plasma levels.^[@bibr38-2050312120918264][@bibr39-2050312120918264]--[@bibr40-2050312120918264]^ Even doubling up the dose (300 mg instead of 150 mg) is not sufficient,^[@bibr41-2050312120918264]^ but it can increase the incidence of DIILD, even without the presence of a polymorphism in one or several of these enzymes. As variability in drug response among patients is multifactorial, genetic variations in metabolizing enzymes may enhance the drivers of DIILD. Both clinical and genetic risk stratification (pharmacogenomics) may lead to a more accurate prevention of drug-induced lung damage in the future.

Our study has some limitations that should be considered. First, the JADER database does not contain detailed background information, such as genetic information, lifestyle habit (e.g. smoking), medical history (e.g. treatment regimen and pre-existing lung disease). For example, as detailed information is lacking from the studied population, factors affecting latency time (time to occurrence of the DIILD), such as concomitant infections that increase the degree of oxidative stress and cell injury or the occurrence of renal impairment, that influence pharmacokinetics and therefore serum drug levels,^[@bibr2-2050312120918264],[@bibr42-2050312120918264]^ are not evaluated. Second, the SRS is subject to over-reporting, under-reporting, missing data, exclusion of data from healthy individuals, lack of a denominator, and presence of confounding factors.^[@bibr9-2050312120918264]^ Therefore, ROR is not applicable to inferences of comparative degrees of causality. ROR only offers a rough indication of signal strength. Several approaches can be used to control for covariates, such as multiple-logistic regression,^[@bibr43-2050312120918264]^ Bayesian logistic regression,^[@bibr44-2050312120918264]^ and propensity score.^[@bibr45-2050312120918264]^ These approaches may be useful for further analysis of SRS. Third, in the association rule mining method, the researcher determined the parameters (*support, confidence*, and *maxlen*) according to the data set and purpose of the research. Therefore, further epidemiological studies may be required to confirm the results of this study.

Conclusion {#section16-2050312120918264}
==========

Despite the limitations inherent to the SRS, we showed the potential risk of DIILD in a real-life setting. The present analysis showed that patients receiving gefitinib, erlotinib, afatinib, or crizotinib should be closely monitored for the development of DIILD within a short duration (4 weeks). In contrast, patients receiving methotrexate, leflunomide, etanercept, amiodarone, or PEG INF-2α should be carefully monitored for the development of DIILD over a longer duration (more than 4 months). Patients who are co-administered amiodarone, sho-saiko-to, and sho-saiko-to-ka-kikyo-sekko should also be carefully monitored for the development of DIILD.
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